PRIMO Post-Market Clinical Follow Up Study (PRIMO)
Primary Purpose
Open Surgery, Blood Vessels, Lymphatic Ducts and Nerves, Free Flaps
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Symani Surgical System
Sponsored by

About this trial
This is an interventional treatment trial for Open Surgery focused on measuring microsurgery, RASM, free flap, lymphatic ducts, Symani
Eligibility Criteria
Inclusion Criteria:
- Patients who need a reconstructive procedure and a microsurgical reconstruction is deemed the best option by the plastic, orthopedic or other surgeon in response to a post-oncological, post-traumatic or congenital tissue defect or to treat lymphedema.
- Patients who have been selected by the Clinical Registry Manager at the Clinical Center as appropriate candidates for treatment with RASM in accordance with the Instruction For Use (IFU).
- Subjects who fit the criteria to perform surgery requiring reconstructions using free flaps, replantations or lymphatic reconstructions.
- Subjects who agree to have the surgery and the anesthesia.
- Subjects who voluntarily decide to participate in this registry with the surgery performed with the aid of the RASM Surgical System and sign the Informed Consent Form
Exclusion Criteria:
- Subjects who have bleeding or coagulation disorders in the past or present.
- Any criteria that preclude prolonged anesthesia.
- History of anaphylaxis or severe complicated allergy symptoms.
- Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders or previous mental disorders that may significantly affect the data collection or the ability to comply with the protocol.
- Evidence or history of autoimmune disease or compromised immune system.
- Participation in another clinical trial within 4 weeks prior to participation in the registry.
- Subjects belonging to vulnerable populations or ineligible to participate for other reasons by a Clinical Registry Manager at a Clinical Center.
- Subjects with pacemaker
Sites / Locations
- LKH Salzburg, Universitätsklinik für Mund-, Kiefer- und GesichtschirurgieRecruiting
- Universitair Ziekenhuis BrusselRecruiting
- Klinik für Mund-, Kiefer- und Gesichtschirurgie UKSH KielRecruiting
- Fachklinik HornheideRecruiting
- Istituto Ortopedico RizzoliRecruiting
- Azienda Ospedaliera Universitaria Careggi
- Hospital de la Santa Creu i Sant PauRecruiting
- University Hospital ZurichRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Robotic Assisted Microsurgery
Arm Description
Patients who meet the eligibility criteria for the study and undergo a microsurgical reconstruction using the Symani System according to its indications for use.
Outcomes
Primary Outcome Measures
Procedure Robotic Success
Ability to complete the surgical task with Symani as intended by the surgeon
Secondary Outcome Measures
Anastomosis time
Time to execute each anastomosis
Intraoperative redo
Intraoperative need to repeat anastomosis
Postoperative redo
Postoperative need to repeat anastomosis
Complications
Major or minor complications
Free Flap/Replantation Failure
Failure of the free flap or replantation
Limb volume reduction (for lymphatic surgery)
Limb volume reduction
Warm ischemia time
Time for warm ischemia
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04843436
Brief Title
PRIMO Post-Market Clinical Follow Up Study
Acronym
PRIMO
Official Title
Post-Market, Non-Randomized, Multicentre PMCF Study to Monitor the Safety and Performance of Symani System in Microsurgical Reconstructive Procedures in a Real Life Setting
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 13, 2021 (Actual)
Primary Completion Date
April 1, 2026 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MMI Spa
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Post Market Clinical Follow up Study aimed to collect clinical data on safety and efficacy of Robotically Assisted System called Symani to perform microsurgery techniques such as anastomosis, suturing and ligation for open surgery procedures on small anatomical structures such as blood vessels, lymphatic ducts and nerves.
Detailed Description
PMCF study aimed to monitor the safety, usability, performance and long-term efficacy of Symani. Furthermore, it will permit to detect potential emerging risks related to safety on the basis of clinical evidence through the observation of patients who have undergone microsurgical reconstructions using the Symani Surgical System in the usual setting of standard surgical practice.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Surgery, Blood Vessels, Lymphatic Ducts and Nerves, Free Flaps
Keywords
microsurgery, RASM, free flap, lymphatic ducts, Symani
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
420 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Robotic Assisted Microsurgery
Arm Type
Experimental
Arm Description
Patients who meet the eligibility criteria for the study and undergo a microsurgical reconstruction using the Symani System according to its indications for use.
Intervention Type
Device
Intervention Name(s)
Symani Surgical System
Intervention Description
Robotically Assisted Microsurgery
Primary Outcome Measure Information:
Title
Procedure Robotic Success
Description
Ability to complete the surgical task with Symani as intended by the surgeon
Time Frame
Procedure
Secondary Outcome Measure Information:
Title
Anastomosis time
Description
Time to execute each anastomosis
Time Frame
Procedure
Title
Intraoperative redo
Description
Intraoperative need to repeat anastomosis
Time Frame
Procedure
Title
Postoperative redo
Description
Postoperative need to repeat anastomosis
Time Frame
7 days
Title
Complications
Description
Major or minor complications
Time Frame
30 days
Title
Free Flap/Replantation Failure
Description
Failure of the free flap or replantation
Time Frame
30 days
Title
Limb volume reduction (for lymphatic surgery)
Description
Limb volume reduction
Time Frame
24 weeks
Title
Warm ischemia time
Description
Time for warm ischemia
Time Frame
Procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients aged >18
Patients who need a reconstructive procedure and a microsurgical reconstruction is deemed the best option by the plastic, orthopedic or other surgeon in response to a post-oncological, post-traumatic or congenital tissue defect or to treat lymphedema.
Patients who have been selected by the Clinical Registry Manager at the Clinical Center as appropriate candidates for treatment with RASM in accordance with the Instruction For Use (IFU).
Subjects who fit the criteria to perform surgery requiring reconstructions using free flaps, replantations or lymphatic reconstructions.
Subjects who agree to have the surgery and the anesthesia.
Subjects who voluntarily decide to participate in this registry with the surgery performed with the aid of the RASM Surgical System and sign the Informed Consent Form
Exclusion Criteria:
Subjects who have bleeding or coagulation disorders in the past or present.
Any criteria that preclude prolonged anesthesia.
History of anaphylaxis or severe complicated allergy symptoms.
Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders or previous mental disorders that may significantly affect the data collection or the ability to comply with the protocol.
Evidence or history of autoimmune disease or compromised immune system.
Participation in another clinical trial within 4 weeks prior to participation in the registry.
Subjects belonging to vulnerable populations or ineligible to participate for other reasons by a Clinical Registry Manager at a Clinical Center.
Subjects with pacemaker
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elisa Scaccianoce
Phone
+39 050 879692
Email
elisa.scaccianoce@mmimicro.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jake Gilson
Email
jake.gilson@mmimicro.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marco Innocenti, Prof.
Organizational Affiliation
Istituto Ortopedico Rizzoli Bologna
Official's Role
Principal Investigator
Facility Information:
Facility Name
LKH Salzburg, Universitätsklinik für Mund-, Kiefer- und Gesichtschirurgie
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Enzinger, MD
Email
s.enzinger@salk.at
First Name & Middle Initial & Last Name & Degree
Gian Battista Bottini, MD
First Name & Middle Initial & Last Name & Degree
Simon Enzinger, MD
Facility Name
Universitair Ziekenhuis Brussel
City
Brussel
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandru Nistor, MD
Email
alexandru.nistor@uzbrussel.be
First Name & Middle Initial & Last Name & Degree
Moustapha Hamdi, Prof
First Name & Middle Initial & Last Name & Degree
Alexandru Nistor, MD
First Name & Middle Initial & Last Name & Degree
Ayush Kapila, MD
Facility Name
Klinik für Mund-, Kiefer- und Gesichtschirurgie UKSH Kiel
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorg Wiltfang, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Henning Wieker, MD
Email
henning.wieker@uksh.de
First Name & Middle Initial & Last Name & Degree
Jorg Wiltfang, Prof
First Name & Middle Initial & Last Name & Degree
Henning Wieker, MD
Facility Name
Fachklinik Hornheide
City
Münster
ZIP/Postal Code
48157
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maximilian Kueckelhaus, MD
Email
maximilian.kueckelhaus@fachklinik-hornheide.de
First Name & Middle Initial & Last Name & Degree
Maximilian Kueckelhaus, MD
Facility Name
Istituto Ortopedico Rizzoli
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Mori, MD
Email
francesco.mori@ior.it
First Name & Middle Initial & Last Name & Degree
Francesco Mori, MD
Facility Name
Azienda Ospedaliera Universitaria Careggi
City
Firenze
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaume Masia, MD
Email
jmasia@santpau.cat
First Name & Middle Initial & Last Name & Degree
Gemma Pons, MD
Email
gponsp@santpau.cat
First Name & Middle Initial & Last Name & Degree
Jaume Masia, MD
First Name & Middle Initial & Last Name & Degree
Gemma Pons, MD
Facility Name
University Hospital Zurich
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Lindenblatt, Prof.
Email
nicole.lindenblatt@usz.ch
First Name & Middle Initial & Last Name & Degree
Nicole Lindenblatt, Prof.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PRIMO Post-Market Clinical Follow Up Study
We'll reach out to this number within 24 hrs